2021 Benchmark

Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.

The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.

Large R&D-based companies

84%
GSK
Projects in the pipeline: 31
Products on the market: 51
Score breakdown
Research & Development: 93%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
81%
Pfizer
Projects in the pipeline: 13
Products on the market: 116
Score breakdown
Research & Development: 77%
Responsible Manufacturing: 80%
Appropriate Access: 80%
Stewardship: 90%
68%
Johnson & Johnson
Projects in the pipeline: 14
Products on the market: 8
Score breakdown
Research & Development: 50%
Responsible Manufacturing: 80%
Appropriate Access: 72%
Stewardship: 80%
63%
Novartis
Projects in the pipeline: N/A
Products on the market: 109
Score breakdown
Research & Development: 7%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
60%
Sanofi
Projects in the pipeline: 6
Products on the market: 47
Score breakdown
Research & Development: 33%
Responsible Manufacturing: 73%
Appropriate Access: 84%
Stewardship: 60%
58%
Shionogi
Projects in the pipeline: 11
Products on the market: 8
Score breakdown
Research & Development: 70%
Responsible Manufacturing: 93%
Appropriate Access: 4%
Stewardship: 80%
57%
Otsuka
Projects in the pipeline: 4
Products on the market: 1
Score breakdown
Research & Development: 56%
Responsible Manufacturing: 43%
Appropriate Access: 60%
Stewardship: 65%
46%
MSD
Projects in the pipeline: 13
Products on the market: 19
Score breakdown
Research & Development: 47%
Responsible Manufacturing: 73%
Appropriate Access: 29%
Stewardship: 55%

Generic medicine manufacturers

71%
Aurobindo
Projects in the pipeline: N/A
Products on the market: 39
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 60%
Stewardship: 87%
69%
Abbott
Projects in the pipeline: N/A
Products on the market: 85
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 53%
Stewardship: 80%
67%
Viatris
Projects in the pipeline: N/A
Products on the market: 87
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 72%
Stewardship: 53%
63%
Fresenius Kabi
Projects in the pipeline: N/A
Products on the market: 51
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 53%
Stewardship: 80%
60%
Cipla
Projects in the pipeline: N/A
Products on the market: 59
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 40%
Stewardship: 87%
60%
Teva
Projects in the pipeline: N/A
Products on the market: 137
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 47%
Stewardship: 80%
47%
Sun Pharma
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 47%
Stewardship: 60%
20%
Alkem
Projects in the pipeline: N/A
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 20%
Stewardship: 0%
15%
Hainan Hailing
Projects in the pipeline: N/A
Products on the market: 43
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 20%
Appropriate Access: 20%
Stewardship: 0%
Room to improve Performance so far

Insights

  • Progress on limiting antibiotic waste in environment

    More companies are setting and enforcing limits for antibacterial material that can be released in manufacturing wastewaters. Companies generally perform best at implementing these limits at their own factories. However, just 5.2% of third-party manufacturing sites are reported as compliant.

    > To the Key Finding

  • More companies require suppliers to set AMR limits

    Companies generally perform best at setting and monitoring specific AMR-related environmental standards at their own manufacturing sites. For the first time, the Benchmark reports that three generic medicine companies now require suppliers also meet such standards.

    > To the analysis

  • Shionogi is first to publish the details of its antibacterial waste-management performance

    Shionogi has published information on audit results covering wastewater management, solid-waste management and discharge limits. Its disclosure covers all antibacterial APIs and/or drug products produced at its site in Japan and at supplier sites. 

    > To the best practice

  • How pharma companies manage antibacterial waste

    Many factories around the world are involved in the production of antibacterials, with many based in India and China. If these manufacturing sites do not manage their waste appropriately, the discharge of wastewaters containing active pharmaceutical ingredients (APIs) into the environment can trigger resistance.

    > To the analysis


Get in touch

Back to top |